olvi-vec
olvi-vec: sourced relationships with 1 company · 2 clinical trials tracked.
olvi-vec evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could olvi-vec → GNLX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| GENELUX Corp (GNLX) | Phase 3 |
Clinical Trial Registry Records (2)
PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory
Primary endpoint: Evaluate safety of Olvi-Vec in patients from day 1 to end of study
Phase 1b & 2 Study With Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Primary endpoint: Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)
Frequently asked questions
Which companies have sourced relationships with olvi-vec?
olvi-vec has dated SEC/FDA relationship records for GENELUX Corp.
How many clinical trials involve olvi-vec?
BioSniper tracks 2 clinical trials involving olvi-vec.